Review Article
Clinical and Molecular Characteristics Associated with Survival in Advanced Melanoma Treated with Checkpoint Inhibitors
Table 2
Baseline characteristics of patient demographics.
| | CheckMate 037 Larkin et al. 2017 | CheckMate 066 Robert et al. 2015 | CheckMate 067 Wolchok et al. 2017 | CheckMate 069 Hodi et al. 2016 | KEYNOTE-002 Ribas et al. 2015 | KEYNOTE-006 Schachter et al. 2017 |
| Phase | III | III | III | III | II | III |
| No. of Patients | 405 | 418 | 945 | 142 | 540 | 834 |
| Arms | Nivo | ICC | Nivo | Daca | Nivo+Ipi | Nivo | Ipi | Nivo+Ipi | Ipi | Pemb 1 | Pemb 2 | ICC | Pemb 1 | Pemb 2 | Ipi |
| No in arm. | 272 | 133 | 210 | 218 | 314 | 316 | 315 | 95 | 47 | 176 | 177 | 167 | 279 | 277 | 278 |
| Male | 176 | 85 | 121 | 125 | NR1 | NR1 | NR1 | 63 | 32 | 104 | 109 | 114 | 161 | 174 | 162 |
| Female | 96 | 48 | 89 | 83 | NR1 | NR1 | NR1 | 32 | 15 | 76 | 72 | 65 | 118 | 103 | 116 |
| Age in years median | 59 | 62 | 64 | 66 | NR1 | NR1 | NR1 | 64 | 67 | 62 | 60 | 63 | 61 | 63 | 62 |
| ECOG 0 | 162 | 84 | 148 | 121 | 230 | 237 | 224 | 79 | 37 | 98 | 98 | 99 | 196 | 189 | 188 |
| ECOG 1 | 110 | 48 | 60 | 84 | 83 | 79 | 91 | 14 | 10 | 80 | 83 | 80 | 83 | 88 | 90 |
|
|